Opinion|Videos|April 3, 2025
Checkpoint Inhibitors for Treatment of NMIBC
Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In addition to recent approval, several immunotherapies such as PD-(L)-1 inhibitors (durvalumab and sasanlimab) are being evaluated in BCG-unresponsive patients. What are your initial impressions of available data with immunotherapies?
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
4
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
5